NCT04900519: Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with previous exposure to an anti-CD47 or SIRPa antibody (e.g. magrolimab); Patients with known central nervous system (CNS) involvement (e.g. brain metastasis or leptomeningeal disease)

Comments are closed.

Up ↑